Qin R, Zhang Y, Shi J, Wu P, An C, Li Z
Cell Res. 2025; .
PMID: 40011760
DOI: 10.1038/s41422-025-01077-9.
Smith G, Lee M, Jennings E, James J
Discov Immunol. 2025; 4(1):kyae019.
PMID: 39959909
PMC: 11829120.
DOI: 10.1093/discim/kyae019.
Chen X, Leisegang M, Gavvovidis I, Pollack S, Lorenz F, Schumacher T
Front Immunol. 2025; 15():1524629.
PMID: 39776913
PMC: 11703889.
DOI: 10.3389/fimmu.2024.1524629.
Householder K, Xiang X, Jude K, Deng A, Obenaus M, Wilson S
bioRxiv. 2025; .
PMID: 39763827
PMC: 11702606.
DOI: 10.1101/2024.12.16.628822.
Lin P, Lin Y, Mai Z, Zheng Y, Zheng J, Zhou Z
Theranostics. 2025; 15(1):300-323.
PMID: 39744228
PMC: 11667231.
DOI: 10.7150/thno.104594.
A synthetic scaffold to target peptide-MHC complexes.
Balivada P, Gaglione S, Birnbaum M
Nat Biotechnol. 2024; .
PMID: 39672952
DOI: 10.1038/s41587-024-02513-8.
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.
Ribeiro A, Britton-Rivet C, Collins L, Carreira R, Moureau S, Benlahrech A
Immunother Adv. 2024; 4(1):ltae008.
PMID: 39659431
PMC: 11631188.
DOI: 10.1093/immadv/ltae008.
High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells.
Fuchsl F, Untch J, Kavaka V, Zuleger G, Braun S, Schwanzer A
Nat Commun. 2024; 15(1):10520.
PMID: 39627205
PMC: 11615276.
DOI: 10.1038/s41467-024-53911-0.
Broadening alloselectivity of T cell receptors by structure guided engineering.
Karuppiah V, Sangani D, Whaley L, Pengelly R, Uluocak P, Carreira R
Sci Rep. 2024; 14(1):26851.
PMID: 39500929
PMC: 11538495.
DOI: 10.1038/s41598-024-75140-7.
Exploring the potential of structure-based deep learning approaches for T cell receptor design.
Ribeiro-Filho H, Jara G, Guerra J, Cheung M, Felbinger N, Pereira J
PLoS Comput Biol. 2024; 20(9):e1012489.
PMID: 39348412
PMC: 11466415.
DOI: 10.1371/journal.pcbi.1012489.
Focusing on CD8 T-cell phenotypes: improving solid tumor therapy.
Yao Z, Zeng Y, Liu C, Jin H, Wang H, Zhang Y
J Exp Clin Cancer Res. 2024; 43(1):266.
PMID: 39342365
PMC: 11437975.
DOI: 10.1186/s13046-024-03195-5.
Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation.
Brunnberg J, Barends M, Fruhschulz S, Winter C, Battin C, de Wet B
Proc Natl Acad Sci U S A. 2024; 121(22):e2321600121.
PMID: 38771881
PMC: 11145271.
DOI: 10.1073/pnas.2321600121.
Exploring the Potential of Structure-Based Deep Learning Approaches for T cell Receptor Design.
Ribeiro-Filho H, Jara G, Guerra J, Cheung M, Felbinger N, Pereira J
bioRxiv. 2024; .
PMID: 38712216
PMC: 11071404.
DOI: 10.1101/2024.04.19.590222.
Identification and affinity enhancement of T-cell receptor targeting a KRAS cancer neoantigen.
Zhang M, Xu W, Luo L, Guan F, Wang X, Zhu P
Commun Biol. 2024; 7(1):512.
PMID: 38684865
PMC: 11058820.
DOI: 10.1038/s42003-024-06209-2.
T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy.
Li Y, Zhao W, Shen Y, Xu Y, Chen S, Pan L
Biomedicines. 2024; 12(4).
PMID: 38672132
PMC: 11048172.
DOI: 10.3390/biomedicines12040776.
STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells.
Wang L, Liang Z, Guo Y, Habimana J, Ren Y, Amissah O
Cell Death Dis. 2024; 15(4):265.
PMID: 38615022
PMC: 11016101.
DOI: 10.1038/s41419-024-06638-1.
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.
Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y
Exp Hematol Oncol. 2024; 13(1):37.
PMID: 38570883
PMC: 10988985.
DOI: 10.1186/s40164-024-00504-8.
Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement.
Hopkins J, MacLachlan B, Harper S, Sewell A, Cole D
Discov Immunol. 2024; 1(1):kyac001.
PMID: 38566908
PMC: 10917088.
DOI: 10.1093/discim/kyac001.
The recent advancement of TCR-T cell therapies for cancer treatment.
Zhao X, Shao S, Hu L
Acta Biochim Biophys Sin (Shanghai). 2024; 56(5):663-674.
PMID: 38557898
PMC: 11187488.
DOI: 10.3724/abbs.2024034.
NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route.
Amissah O, Chen W, Habimana J, Sun Y, Lin L, Liu Y
Cancer Cell Int. 2024; 24(1):64.
PMID: 38336680
PMC: 10858587.
DOI: 10.1186/s12935-024-03249-w.